Dr. Pavani Chalasani, MD

Dr. Chalasani practices at Medical Faculty Associates, Inc in Washington, District of Columbia.

Dr. Chalasani's NPI, 1689879967, was assigned on June 18, 2007. Dr. Chalasani graduated from Gandhi Medical College in 2002. Dr. Chalasani holds District of Columbia license MD210003151.

Dr. Chalasani's primary practice is Medical Faculty Associates, Inc, at 2150 Pennsylvania NW Ave, Washington, DC 20037 in District Of Columbia County. The practice phone is (202) 741-3350.

Dr. Chalasani's primary practice is Medical Faculty Associates, Inc in Washington, District of Columbia. Dr. Chalasani is also affiliated with The George Washington University Hospital. The medical group on file is The GW Medical Faculty Associates. Dmand AI also links Dr. Chalasani to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chalasani practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Chalasani's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Chalasani is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Chalasani's licenses on file in 3 states: District of Columbia, Arizona and Illinois.

Dmand AI lists breast cancer, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Chalasani treats.

CMS data shows 446 Medicare services from Dr. Chalasani across 7 procedure codes in 2024, for 141 Medicare patients. Medicare paid $35,187 for them. Every service was in an office.

CMS counts 141 Medicare patients who saw Dr. Chalasani in 2024. The largest group is 65 to 74, with 78 patients. 75% of them have cancer, and 73% have high cholesterol. 27% are also on Medicaid. Their average risk score is 1.23, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chalasani's median patient age at 70, with 88% women.

In 2024, Dr. Chalasani wrote 353 Medicare Part D claims for 75 patients. 83% of them were for generic drugs. CMS names the drug for 273 of them, across 7 drugs with 11 or more claims each, at $496,167 in total drug cost. In 2023, CMS named 88 claims across 3 drugs.

Dr. Chalasani accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 67 papers to Dr. Chalasani, published from 2005 to 2025. 2020 was the busiest year, with 9. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Neoplasm Metastasis. Dr. Chalasani has published most often in Breast Cancer Res Treat. Dr. Chalasani's most frequent co-authors are Waqas Arslan, MD, Jennifer Margaret Segar, MD and Daruka Mahadevan, MD, PhD.

Dmand AI links Dr. Chalasani to 22 clinical trials, 7 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Triple Negative Breast Neoplasms. University of Arizona sponsors the most, 9. Open Payments lists research payments to Dr. Chalasani that name 2 trials.

CMS Open Payments shows 128 general payments to Dr. Chalasani from 24 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Novartis Pharmaceuticals Corporation paid the most, $6,937. It also lists 12 research payments totaling $68,814 from 2018 to 2023, naming 2 clinical trials.

Dr. Chalasani graduated from Gandhi Medical College in 2002.

Dr. Chalasani is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.